口腔へん平上皮癌細胞株の産生する血管内皮細胞増殖抑制因子

DOI

書誌事項

タイトル別名
  • Idetification of an Endothelial cell growth inhibitory factor produced by oral cancer cell line cultured in protein-tree medium.

抄録

In order to study the effects of squamous cell carcinoma (SCC) on endothelial cell function, supernatants of HSC-3PF, a human SCC line able to growth without serum and any proteins, was examined the effect on cultured bovine artery endothelial cells (BAEC). It inhibited angiognesis by the BAEC in vitro three dimensional culture. The factor in the supernatant of HSC-3PF caused the inhibition of BAEC growth, named endothelial cell inhibitory factor (ECGIF), was partially purified by means of Mono-Q-anion exchange and gel filtrated column chromatography.<BR>ECGIF inhibited the proliferation of BAEC in a dose-dependent manner, and the inhibitory activity was reversible. The inhibitory effect was specific to endothelial cells, but not to other types of cells, such as smooth muscle cells, fibroblasts. ECGIF also affected cell morphology of BAEC, that is, it induced cell contraction. For further purification, ECGIF was applied on Superose 12 HR chromatography. The inhibitory activity was found in the flow through fraction. SDS-PAGE analysis of ECGIF showed that there detected 2 bands at 90-kDa and 70-kDa. To identify ECGIF with TGF-β1 or TNF-α, we examined the colony formation of NRK-49F in soft agar in the absence of EGF and the growth of L-M cells. ECGIF stimulated the colony formation of NRK-49 F, but it did not affect L-M cell growth. Moreover the antibodies of TGF-β1 or TNF-α failed to abolish the inhibition of BAEC growth by ECGIF. These results indicate that HSC-3PF produced ECGIF is distinguished from TGF-β and TNF-α, and regulate endothelial cell growth and morphology.

収録刊行物

詳細情報 詳細情報について

  • CRID
    1390001204683518720
  • NII論文ID
    130004001709
  • DOI
    10.2330/joralbiosci1965.34.126
  • ISSN
    03850137
  • 本文言語コード
    ja
  • データソース種別
    • JaLC
    • Crossref
    • CiNii Articles
  • 抄録ライセンスフラグ
    使用不可

問題の指摘

ページトップへ